Dalbavancin dosage regimens in the treatment of gram-positive infections: a case series and review of the literature
DOI:
https://doi.org/10.46570/utjms-2026-1357Keywords:
dalbavancin, dosage, intravenous antibioticsAbstract
Background: Dalbavancin is approved by the United States Food and Drug Administration (FDA) for one-dose or two-dose regimens in the treatment of acute bacterial skin and skin structure infections (ABSSSIs). This agent may also be utilized off-label for invasive gram-positive infections, but there are no standard dosage recommendations for off-label use (1). We evaluated different dosage regimens used in real-life experiences.
Methods: Medication administration data at ProMedica Health System and The University of Toledo Medical Center was reviewed to identify patients treated with dalbavancin to evaluate the efficacy and safety of common dosing regimens for both invasive and noninvasive gram-positive infections. The primary outcome was treatment failure defined as recurrence or hospitalization due to the same infection within one year. Baseline characteristics between successfully treated and failed groups were compared.
Results: Throughout the 5 years (2016-2021), 131 patients who received dalbavancin were enrolled. 82 (63%) of patients had ABSSSIs. Forty-nine (37%) fell under the category of invasive gram-positive infections. Forty-one patients (31%) of them had failure of treatment.
Of the patients who failed treatment, twenty-three patients received one dose of intravenous dalbavancin, and eighteen patients received at least two doses of dalbavancin. Adverse events were noticeable for one patient with transient rash on the hand and one patient had non Clostridioides difficile diarrhea.
Conclusion: Dalbavancin has been a safe and convenient option for the treatment of gram-positive infections. A regimen of two doses or more of dalbavancin may offer a better outcome than one dose only for both invasive and non-invasive gram-positive infections.
References
E. Bouza, M. Valerio, A. Soriano, L. Morata, E.G. Carus, C. Rodríguez-González et al., Dalbavancin in the treatment of different gram-positive infections: a real-life experience, Int. J. Antimicrob. Agents 51 (2018), pp. 571–577.
P. Koomanachai, J.L. Crandon and D.P. Nicolau, Newer developments in the treatment of Gram-positive infections, Expert Opin. Pharmacother. 10 (2009), pp. 2829–2843.
J.R. Smith, K.D. Roberts and M.J. Rybak, Dalbavancin: A Novel Lipoglycopeptide Antibiotic with Extended Activity Against Gram-Positive Infections, Infect. Dis. Ther. 4 (2015), pp. 245–258.
dalbavancin. Available at https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-dalvance-dalbavancin.
F. Bai, C. Aldieri, A. Cattelan, F. Raumer, E. Di Meco, M.C. Moioli et al., Efficacy and safety of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and other infections in a real-life setting: data from an Italian observational multicentric study (DALBITA study), Expert Rev. Anti Infect. Ther. 18 (2020), pp. 1271–1279.
T. Morrisette, M.A. Miller, B.T. Montague, G.R. Barber, R.B. McQueen and M. Krsak, On- and off-label utilization of dalbavancin and oritavancin for Gram-positive infections, J. Antimicrob. Chemother. 74 (2019), pp. 2405–2416.
U. Rappo, S. Puttagunta, V. Shevchenko, A. Shevchenko, A. Jandourek, P.L. Gonzalez et al., Dalbavancin for the Treatment of Osteomyelitis in Adult Patients: A Randomized Clinical Trial of Efficacy and Safety, Open Forum Infect. Dis. 6 (2019), pp. ofy331.
oritavancin. Available at https://www.fda.gov/drugs/development-resources/oritavancin-diphosphate-injection.
Dinh, C. Duran, P. Pavese, L. Khatchatourian, B. Monnin, A. Bleibtreu et al., French national cohort of first use of dalbavancin: A high proportion of off-label use, Int. J. Antimicrob. Agents 54 (2019), pp. 668–672.
T. Lampejo, Dalbavancin and telavancin in the treatment of infective endocarditis: a literature review, Int. J. Antimicrob. Agents 56 (2020), pp. 106072.
M.P. Veve, N. Patel, Z.A. Smith, S.D. Yeager, L.R. Wright and M.A. Shorman, Comparison of dalbavancin to standard-of-care for outpatient treatment of invasive Gram-positive infections, Int. J. Antimicrob. Agents 56 (2020), pp. 106210.
A.C. Streifel, L.C. Strnad, M.K. Sikka, C.D. Varley, J. Makadia, E. Sukerman et al., Dalba Got Back? Use of Dalbavancin for the Treatment of Vertebral Osteomyelitis, Open Forum Infect. Dis. 11 (2024), pp. ofae070.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Hend Elsaghir, Abdelrhman Mohamed, MD, Masharib Bashar, MD, Mathew Rico, Pharm D, Avery Lewis, Joel Kammeyer,MD, Zachary Gruss, PharmD, BCIDP, Abhishiek Setia,MD, Salman Arif,MD (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC BY 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
